Neurorehabilitation News

JCR Pharmaceuticals Co. has entered into an agreement with AstraZeneca’s Rare Disease division, Alexion, to develop a novel therapeutic molecule for the treatment of neurodegenerative disease.

Hyperbaric oxygen therapy improved pain symptoms, quality of life and social and emotional function in adults with fibromyalgia after traumatic brain injury compared with pharmacologic intervention, according to research in PLOS One.

Prilenia Therapeutics announced the completion of its global phase 3 study of pridopidine for Huntington’s disease, with topline results expected in the next few months.

Steroid use for at least 10 days before surgery was significantly associated with infectious and noninfectious complications, hospital readmissions and mortality in patients undergoing craniotomy for brain tumors, according to research.

Neuraly has announced that its investigational NLY01 did not meet the primary study endpoint of improvement in motor symptoms in patients with early, untreated Parkinson’s disease.

Ataluren preserved muscle burst activity across a range of ambulatory tests compared with placebo in boys with nonsense mutation Duchenne muscular dystrophy, according to a poster at the 2023 MDA Clinical & Scientific Conference.

Treatment with givinostat was associated with improvement in mobility and physical function compared with placebo in ambulant boys with Duchenne muscular dystrophy, according to a poster at the 2023 MDA Clinical & Scientific Conference.

Eterna Therapeutics Inc. announced it has entered into an exclusive option and license agreement with Lineage Cell Therapeutics Inc. to create novel induced hypoimmune pluripotent stem cell lines for use in cell transplant therapies.

Results of a randomized, double-blind trial showed that hyperbaric oxygen therapy improved cognitive and behavioral function in children experiencing persistent post-concussion syndrome, as published in Scientific Reports.

Horizon Therapeutics recently announced new MRI imaging data from a phase 3 clinical trial, which demonstrated that Uplizna reduced formation of asymptomatic optic nerve lesions in patients with neuromyelitis optica spectrum disorder.